Payment overview · 2025
General Payments
$1,274.76
66 reported records · 12 companies
Healthcare provider profile · identity verified
Ivan Rivera, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKELAND, FL · NPI 1720214190
Verified facts
What the public records show
CMS Open Payments records show Ivan Rivera, MD received $1,274.76 in general payments during 2025 across 66 reported records.
PFIZER INC. accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 431 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 330 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $321.98 | 25.3% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $280.91 | 22.0% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $229.92 | 18.0% | 12 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $211.79 | 16.6% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.60 | 4.4% | 2 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $36.71 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $36.23 | 2.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.65 | 2.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.96 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.47 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.12 | 1.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.42 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,274.76 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $311.62 | 16 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $211.79 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $167.21 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $167.21 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $140.35 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $113.70 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $96.39 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.57 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $56.60 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.68 | 2 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $36.71 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $36.71 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $36.23 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $10.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 330 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 34 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 431 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 25 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 125 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 83 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
103 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
154 | 153 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
56 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
83 | 21 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
431 | 89 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
125 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
330 | 89 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1038 | 336 |
| Amlodipine Besylate | Amlodipine Besylate | 802 | 263 |
| Lisinopril | Lisinopril | 668 | 206 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 665 | 217 |
| Levothyroxine Sodium | Levothyroxine Sodium | 633 | 184 |
| Losartan Potassium | Losartan Potassium | 627 | 195 |
| Pantoprazole Sodium | Pantoprazole Sodium | 559 | 178 |
| Hydrochlorothiazide | Hydrochlorothiazide | 510 | 157 |
| Metformin Hcl | Metformin Hcl | 503 | 173 |
| Gabapentin | Gabapentin | 459 | 127 |
| Ozempic | Semaglutide | 431 | 89 |
| Furosemide | Furosemide | 426 | 133 |
| Tamsulosin Hcl | Tamsulosin Hcl | 389 | 115 |
| Omeprazole | Omeprazole | 381 | 120 |
| Trazodone Hcl | Trazodone Hcl | 372 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 362 | 117 |
| Simvastatin | Simvastatin | 347 | 103 |
| Eliquis | Apixaban | 330 | 89 |
| Montelukast Sodium | Montelukast Sodium | 315 | 114 |
| Metoprolol Tartrate | Metoprolol Tartrate | 301 | 94 |
| Carvedilol | Carvedilol | 278 | 92 |
| Duloxetine Hcl | Duloxetine Hcl | 272 | 83 |
| Clonazepam | Clonazepam | 259 | 57 |
| Meloxicam | Meloxicam | 246 | 74 |
| Tizanidine Hcl | Tizanidine Hcl | 239 | 116 |
| Allopurinol | Allopurinol | 215 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 215 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 200 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 198 | 82 |
| Alprazolam | Alprazolam | 195 | 46 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 192 | 70 |
| Tramadol Hcl | Tramadol Hcl | 191 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 68 |
| Famotidine | Famotidine | 187 | 62 |
| Glipizide | Glipizide | 171 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 52 |
| Methylprednisolone | Methylprednisolone | 163 | 136 |
| Sertraline Hcl | Sertraline Hcl | 159 | 47 |
| Farxiga | Dapagliflozin Propanediol | 158 | 36 |
| Jardiance | Empagliflozin | 158 | 36 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 154 | 153 |
| Ezetimibe | Ezetimibe | 151 | 51 |
| Rybelsus | Semaglutide | 125 | 33 |
| Doxazosin Mesylate | Doxazosin Mesylate | 124 | 34 |
| Mirtazapine | Mirtazapine | 122 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 121 | 33 |
| Lorazepam | Lorazepam | 118 | 23 |
| Mounjaro | Tirzepatide | 117 | 30 |
| Spironolactone | Spironolactone | 117 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 115 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 37 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 107 | 31 |
| Potassium Chloride | Potassium Chloride | 103 | 43 |
| Synthroid | Levothyroxine Sodium | 103 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 102 | 82 |
| Finasteride | Finasteride | 100 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 98 | 28 |
| Atenolol | Atenolol | 97 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 28 |
| Enalapril Maleate | Enalapril Maleate | 95 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 90 | 29 |
| Warfarin Sodium | Warfarin Sodium | 90 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 23 |
| Bupropion Xl | Bupropion Hcl | 83 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 21 |
| Pregabalin | Pregabalin | 81 | 15 |
| Azithromycin | Azithromycin | 78 | 69 |
| Fenofibrate | Fenofibrate | 77 | 24 |
| Metformin Hcl Er | Metformin Hcl | 77 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 19 |
| Dutasteride | Dutasteride | 72 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 23 |
| Lovastatin | Lovastatin | 71 | 21 |
| Xarelto | Rivaroxaban | 70 | 25 |
| Glimepiride | Glimepiride | 69 | 26 |
| Januvia | Sitagliptin Phosphate | 68 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 19 |
| Clonidine Hcl | Clonidine Hcl | 64 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 17 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 63 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 26 |
| Alendronate Sodium | Alendronate Sodium | 59 | 22 |
| Propranolol Hcl | Propranolol Hcl | 59 | 13 |
| Repatha Syringe | Evolocumab | 58 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 56 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 18 |
| Chlorthalidone | Chlorthalidone | 55 | 16 |
| Sucralfate | Sucralfate | 55 | 23 |
| Donepezil Hcl | Donepezil Hcl | 54 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 37 |
| Topiramate | Topiramate | 50 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 47 | 11 |
| Valacyclovir | Valacyclovir Hcl | 45 | 26 |
| Nifedipine Er | Nifedipine | 44 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 29 |
| Kerendia | Finerenone | 42 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 41 | 18 |
| Naproxen | Naproxen | 41 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 36 |
| Ventolin Hfa | Albuterol Sulfate | 41 | 23 |
| Vraylar | Cariprazine Hcl | 41 | suppressed |
| Ketoconazole | Ketoconazole | 40 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 35 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 17 |
| Linzess | Linaclotide | 37 | 18 |
| Telmisartan | Telmisartan | 37 | 11 |
| Acyclovir | Acyclovir | 36 | suppressed |
| Bumetanide | Bumetanide | 36 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 32 |
| Nitroglycerin | Nitroglycerin | 36 | 15 |
| Tradjenta | Linagliptin | 36 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 11 |
| Gemtesa | Vibegron | 34 | 13 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Glipizide Er | Glipizide | 33 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | 12 |
| Buspirone Hcl | Buspirone Hcl | 31 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 11 |
| Digoxin | Digoxin | 30 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | 11 |
| Nystatin | Nystatin | 29 | 21 |
| Ramipril | Ramipril | 29 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Diazepam | Diazepam | 27 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | 12 |
| Jantoven | Warfarin Sodium | 24 | suppressed |
| Minoxidil | Minoxidil | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 15 |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 15 |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 16 |
| Estradiol | Estradiol | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Oxaprozin | Oxaprozin | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Indapamide | Indapamide | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Silodosin | Silodosin | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Trimethoprim | Trimethoprim | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,274.76 · 66 records | PFIZER INC. | Auvelity, Cologuard Collection Kit, ELIQUIS, EVENITY, GEMTESA, LEQVIO, NURTEC ODT, Natroba, Ozempic, PAXLOVID, QULIPTA, Rybelsus, Spinosad, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error